Victory Capital Management Inc. Has $28.92 Million Position in Johnson & Johnson (JNJ)

Victory Capital Management Inc. increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 40.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 222,470 shares of the company’s stock after buying an additional 63,633 shares during the period. Victory Capital Management Inc.’s holdings in Johnson & Johnson were worth $28,924,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in shares of Johnson & Johnson by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after purchasing an additional 3,023,110 shares during the last quarter. BlackRock Inc. increased its position in shares of Johnson & Johnson by 2.6% in the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after purchasing an additional 4,332,612 shares during the last quarter. FMR LLC increased its position in shares of Johnson & Johnson by 5.9% in the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock worth $3,603,268,000 after purchasing an additional 1,509,745 shares during the last quarter. Capital World Investors increased its position in shares of Johnson & Johnson by 4.1% in the 2nd quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock worth $3,507,009,000 after purchasing an additional 1,050,000 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its position in shares of Johnson & Johnson by 4.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 17,860,047 shares of the company’s stock worth $2,363,788,000 after purchasing an additional 771,039 shares during the last quarter. 65.70% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Johnson & Johnson (NYSE:JNJ) opened at $145.76 on Friday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a 1 year low of $110.76 and a 1 year high of $146.42. The firm has a market cap of $391,590.00, a PE ratio of 25.31, a P/E/G ratio of 2.75 and a beta of 0.80.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. The firm had revenue of $19.65 billion during the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. Johnson & Johnson’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.68 EPS. research analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.31%. The ex-dividend date of this dividend is Monday, February 26th. Johnson & Johnson’s payout ratio is 58.33%.

Several research firms have recently weighed in on JNJ. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 target price for the company in a research report on Thursday. Wells Fargo & Co reissued an “outperform” rating and issued a $160.00 target price (up previously from $155.00) on shares of Johnson & Johnson in a research report on Friday. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. JPMorgan Chase & Co. downgraded shares of Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Finally, Citigroup began coverage on shares of Johnson & Johnson in a research report on Monday, September 25th. They set a “neutral” rating and a $140.00 price objective for the company. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $145.94.

COPYRIGHT VIOLATION WARNING: This news story was posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://www.thelincolnianonline.com/2018/01/14/victory-capital-management-inc-has-28-92-million-position-in-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply